Login / Signup

Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations.

Soojin JunSehhoon ParkJong-Mu SunSe-Hoon LeeJin Seok AhnMyung-Ju AhnJuhee ChoHyun Ae Jung
Published in: Cancers (2023)
mutations demonstrated relatively long-duration benefits of ICI therapy. PD-L1 was a significant positive predictive biomarker in all AGA groups.
Keyphrases
  • genome wide
  • stem cells
  • bone marrow
  • mesenchymal stem cells
  • skeletal muscle
  • glycemic control
  • replacement therapy